Home > Crofelemer, diarrhea, diarrhoea, medical > NAPO pushes Crofelemer for Pediatric Populations

NAPO pushes Crofelemer for Pediatric Populations

Thu, 08Oct2009

Excerpt From Napo press release:

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Napo Pharmaceuticals, Inc. (Napo) recently hosted an educational panel to address the impact of the lack of access to clean water and enteric disease on global health, the environment, and human rights. Robert F. Kennedy, Jr., Napo’s Environmental Advisor, discussed the negative consequences of non-sustainable development on indigenous peoples and the environment.

Other speakers included E. Benjamin Skinner, who has written about the connection between the war on diarrhea and modern-day slavery in his book, A Crime So Monstrous; and James Workman, whose book, Heart of Dryness, details the current and future struggles surrounding the scarcity of clean water, as told through the experiences and traditional wisdom of bushmen in southern Africa’s Kalahari region. Dr. Pradip Bardhan of the International Centre for Diarrhoeal Disease Research in Bangladesh (ICDDR,B), a state-of-the-art cholera hospital, shared his experiences with enteric disease, not only at the ICDDR,B, but also with respect to cholera crises around the world, such as the recent outbreak in Zimbabwe.

“This event was an important gathering of world experts to address the various factors affecting the health of global populations,” said Napo CEO Lisa Conte. “The development of crofelemer, Napo’s investigational drug for secretory pediatric infectious diarrhea, is part of an effort by many partners to address the devastating dehydration in pediatric populations, regardless of their geography of social or economic status.”

Napo invites you to view highlights of the discussion at http://vimeo.com/6819224. You may view the entire hour-long event at http://vimeo.com/6819500.

The panel event followed a recent discussion among international experts on Napo’s global advisory board about the development of crofelemer for use in pediatric population. In addition, on Oct. 2, Ms. Conte addressed the MIT Legatum Center’s second annual Progress Through Innovation conference, which highlights the development and empowerment of people in developing regions of the world. Ms. Conte’s remarks focused on Napo’s global business plan to bring its first-in-class anti-diarrheal agent, crofelemer, to all populations in all countries through a sustainable business model by working with local partners. She also commented on the human-rights impacts and environmental repercussions of unmet global health needs, and the common traits shared by innovators and entrepreneurs around the globe.

Crofelemer for Pediatric Populations (CRO-PED)

Napo is organizing a program to accelerate the development of crofelemer for pediatric infectious diarrheal diseases, targeting regulatory approval in 2011-2012 (pending additional funding). The company has established a global advisory board to ensure that the development of a pediatric product incorporates World Health Organization (WHO) Essential Medicines guidelines for oral rehydration solution (ORS), zinc, etc., and to generate a formulation that is practical and safe for resource-constrained regions with limited health personnel. Napo has formed alliances with Direct Relief International and others to make crofelemer accessible to every childhood population in need. Napo is also in the planning stages for clinical development of crofelemer for severe cholera in pediatric populations at the ICDDR,B.

About Crofelemer

Napo’s proprietary patented gastrointestinal compound, crofelemer, is a first-in-class anti-secretory agent extracted from Croton lechleri, a medicinal plant sustainably harvested in several South American countries. Crofelemer is in various stages of clinical development for four distinct programs, including a late-stage Phase 3 program. The FDA has granted fast-track status to crofelemer development for IBS and HIV-related indications (CRO-IBS and CRO-HIV):

  • CRO-HIV for HIV-related diarrhea, Phase 3 (under Special Protocol Assessment)
  • CRO-IBS for diarrhea irritable bowel syndrome (D-IBS), Phase 2
  • CRO-ID for acute infectious diarrhea (including cholera), Phase 2
  • CRO-PED for pediatric diarrhea, Phase 1

Napo’s licensee, Salix Pharmaceuticals, Inc. has exclusive rights to crofelemer for all indications in North America, Europe (excluding Iceland, Liechtenstein, Norway, and Switzerland), and Japan, and, for certain other indications including irritable bowel syndrome, worldwide. Salix estimates that the HIV-associated diarrhea market opportunity alone may be $300 million. The ADVENT trial of crofelemer as a treatment for chronic diarrhea in patients on antiretroviral therapies for HIV or AIDS is being conducted under fast-track status and Special Protocol Assessment agreement with the FDA.

Crofelemer has also been licensed to Glenmark Pharmaceuticals, Ltd. in India and 140 emerging countries for indications related to HIV (CRO-HIV), use in acute adult infectious diarrhea (CRO-ID), and use in pediatric diarrhea (CRO-PED). Glenmark and Salix have entered into a commercial supply agreement for crofelemer active pharmaceutical ingredient (API). AsiaPharm Group, Ltd. has rights to crofelemer in China (including Hong Kong and Macau).

washlink notes

see Journal of Pediatric Gastroenterology and Nutrition: for more information on Infectious Diarrhea in Children

see google journal search  results for studies with Crofelemer

washlink boarder2

S a n i t a t i o n

Linking the drops of knowledge to form a stream of WASH information: WATSAN, Sanitation, Water, Hygiene, and Global Health

WASH Finance

Costs and funding of water, sanitation and hygiene (WASH) services for all


Gonzalo Bacigalupe, EdD, MPH

Ross Bailey's Blog

Campaigns and digital innovations

Brown, White and Blue

Itinerant New York moves to India and attempts journalist improvement. Hilarity ensues.



A Page from Tom Paulson

Global Health, Science and Journalism


Just another WordPress.com site

Source News Service Feedback's Blog

Focus Group Interviews to mesure spread, use and impact of IRC Services

Sustainable Sanitation in Emergency & Reconstruction

News of developments and innovations - collected by SuSanA working group 8

Peter J Bury 4 IRC

A journey into a "using a Blog for work" experience @ IRC International Water and Sanitation Centre

Insourced- Dr. Kate Tulenko

Thoughts on a healthier world

The Political Economy of Water Project

About water politics, economics, and other issues surrounding this vital resource.

Dutch Indian Heritage

Sharing history

Environmental Engineering Engenharia do Ambiente

This group aims sharing opportunities between Environmental Engineers / Este grupo tem como objectivo partilhar oportunidades entre profissionais de Engenharia do Ambiente (English / Português)

Global Health Dispatch

Diaries from the Field

WashMedia-South Asia

Forum of South Asian journalists working on Water, Sanitation and Hygiene

%d bloggers like this: